Palbociclib Update

Abstract

PC is a strong and selective inhibitor of CDK4 and -6 that has a lot of effect in BC models. When used in conjunction with letrozole, it has been demonstrated to dramatically increase progression-free survival in the treatment of advanced breast cancer that contains an estrogen receptor. Therefore, we assessed the mechanism, pharmacokinetics, dose, method, administration, and patient acceptability of PC in this review paper.